Approved for use through 10/31/2002, OMI US Patent & Trademark Office U.S. DEPARTMENT OF C pn of information unless it contains a valid OMB contr

Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 10/664,341 STATEMENT BY APPLICANT September 16, 2003 Filing Date (Use as meny sheets as necessery) Zdanovsky, Alexey First Named Inventor **Group Art Unit** 1652 **Examiner Name** Pak, Yong

Attorney Docket No: 341.021US1 Sheet 1 of 1

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		"European Patent Application No. 03754599.3 (Atty Ref 341.021EP1),	
		Communication Pursuant to Article 96(2) EPC mailed 1-25-07", 4 pgs.	
		"European Patent Application No. 03754599.3 (Atty Ref 341.021EP1),	
		Communication pursuant to Article 96(2) mailed 5-22-07", 5 pgs.	
		"European Patent Application No. 03754599.3 (Atty Ref 341.021EP1),	
		Supplemental European Search Report mailed 8-4-2006", 7 pgs.	
		"European Patent Application No. 03754599.3 (Atty Ref 341.021EP1),	
		Supplemental Partial European Search Report mailed 5-17-2006", 5 pgs.	
		"European Patent Application No. 03754599.3 (Atty Ref 341.023EP1), Response	
		filed 4-20-07 to Communication mailed 1-25-07", 17 pgs.	
		"PCT Application No. PCT/US03/28939 (Atty Ref 341.021WO1), International	
		Preliminary Examination Report mailed 10-12-2006", 6 pgs.	
		ADRAIN, C., et al., "Apoptosis-Associated Release of Smac/DIABLO From	
		Mitochondria Requires Active Caspases and is Blocked by Bcl-2", The EMBO	
_		Journal, 20(23), (2001),6627-6636	
		BERKERS, C. R., et al., "Activity Probe for in vivo Profiling of the Specificity of	
		Proteasome Inhibitor Bortezomib", Nature Methods, 2(5), (2005),357-362	
		FERNANDEZ, Y., et al., "Differential Regulation of Noxa in Normal Melanocytes	
		and Melanoma Cells by Proteasome Inhibition: Therapeutic Implications",	
		Cancer Research, 65(14), (2005), 6294-6304	<u> </u>
		KISSELEV, A. F., et al., "Importance of the Different Proteolytic Sites of the	
		Proteasome and the Efficacy of Inhibitors Varies With Protein Substrate", The	
		Journal of Biological Chemistry, 281(13), (March 31, 2006), 8582-8590	
		KISSELEV, A. F., et al., "Monitoring Activity and Inhibition of 26S Proteasomes	
		With Fluorogenic Peptide Substrates", Methods in Enzymology, Vol. 398,	
		(2005),364-378	
		LUKER, G. D., et al., "Imaging 26S Proteasome Activity and Inhibition in Living	
		Mice", Nature Medicine, 9(7), (2003), 969-973	ļ
		RAMSBY, M. L., "Differential Detergent Fractionation of Isolated Hepatocyes:	
		Biochemical, Immunochemical and Two-Dimensional Gel Electrophoresis	
		Characterization of Cytoskeletal and Noncytoskeletal Compartments",	
	L	Electrophoresis, 15, (1994), 265-277	-
		WILKINSON, J. C., et al., "Upstream Regulatory Role for XIAP in Receptor-	
		Mediated Apoptosis", Molecular and Cellular Biology, 24(16), (2004), 7003-7014	<u> </u>

EXAMINER DATE CONSIDERED